MARLBOROUGH, Mass., Jan. 5, 2015 /TRENDINGGLOBALNEWS/ -- RXi Pharmaceuticals Corporation (NASDAQ: RXII),
a biotechnology company focused on discovering, developing and
commercializing innovative therapies addressing major unmet medical
needs using RNA-targeted technologies, today announced that the
Company's President and Chief Executive Officer, Dr. Geert Cauwenbergh, will present at the 7th Annual Biotech Showcase™ 2015 on Monday, January 12, 2015 at 9:30 a.m. PST.
Dr. Cauwenbergh will provide an update on the Company's Dermatology and
Ophthalmology Franchises. He will also discuss business development
opportunities with RXi's broad delivery technology platform as well as
the Company's robust intellectual property portfolio.
The presentation will be webcast and available on the "Investors" section of the Company's website, www.rxipharma.com.
To schedule a meeting with RXi Pharmaceuticals' management team at this conference, contact Investor Relations at ir@rxipharma.com.
About the Biotech Showcase
Co-produced
by Demy-Colton Life Science Advisors and EBD Group, Biotech Showcase is
an investor and partnering conference devoted to providing private and
public biotechnology and life sciences companies an opportunity to
present to, and meet with, investors and pharmaceutical executives
during the course of one of the industry's largest annual healthcare
investor conferences. Investors and biopharmaceutical executives from
around the world gather in San Francisco
during this critical week which is widely viewed as setting the tone
for the coming year. Now in its seventh year, Biotech Showcase is
expected to attract upwards of 1,700 attendees. This conference will
take place January 12-14, 2015 at the Parc 55 Wyndham San Francisco Union Square Hotel, California.
About RXi Pharmaceuticals Corporation
RXi Pharmaceuticals Corporation (NASDAQ: RXII)
is a biotechnology company focused on discovering, developing and
commercializing innovative therapies based on its proprietary,
self-delivering RNAi (sd-rxRNA®) platform. Therapeutics that use RNA
interference, or "RNAi," have great promise because of their ability to
down-regulate the expression of specific genes that may be
over-expressed in disease conditions. Building on the pioneering work of
scientific founder and Nobel Laureate Dr. Craig Mello,
a member of the RXi Scientific Advisory Board, RXi's first RNAi product
candidate, RXI‑109, a self-delivering RNAi compound (sd-rxRNA), entered
into human clinical trials in June 2012
and is currently being evaluated in Phase 2 clinical trials to reduce
the formation of dermal fibrosis (e.g., hypertrophic scars and
keloids). RXI-109 is designed to reduce the expression of connective
tissue growth factor (CTGF), a critical regulator of biological pathways
involved in fibrosis, including scar formation in the skin. RXi's
sd‑rxRNA oligonucleotides are designed for therapeutic use and have
drug-like properties, such as high potency, target specificity, serum
stability, reduced immune response activation, and efficient cellular
uptake. These hybrid oligonucleotide molecules combine the beneficial
properties of conventional RNAi and antisense technologies. This allows
sd‑rxRNAs to achieve efficient cellular uptake and potent, long-lasting
intracellular activity. For more information, please visit www.rxipharma.com.
Forward-Looking Statements
This
communication contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995. Such statements
include, but are not limited to, statements about future expectations,
planned and future development of RXi Pharmaceuticals Corporation's
products, technologies and partnerships. Forward-looking statements
about expectations and development plans of RXi's products and
partnerships involve significant risks and uncertainties such as: the
risk that we may not be able to successfully develop our candidates, or
that development of RNAi-based therapeutics may be delayed or not
proceed as planned, or that we may not develop any RNAi-based products;
risks that the development process for our product candidates may be
delayed, risks related to the development and commercialization of
products by our competitors, the risk related to our ability to control
the timing and terms of collaborations with third parties, the
possibility that other companies or organizations may assert patent
rights preventing us from developing our products. Actual results may
differ from those contemplated by these forward-looking statements. RXi
does not undertake to update forward-looking statements to reflect a
change in its views, events or circumstances that occur after the date
of this communication.
source: http://www.prnewswire.com
0 comments:
Post a Comment